Our Central Nervous System (CNS) Imaging division provides specialized medical imaging expertise for clinical trials evaluating neurological, neurodegenerative, cerebrovascular, psychiatric, and spinal disorders. Supported by a network of more than 100 board-certified and fellowship-trained neuroradiologists, the CNS Imaging division combines deep subspecialty expertise with rigorous, standardized imaging methodologies designed to generate consistent, reproducible, and clinically meaningful data across multicenter and global studies.
Our experience encompasses the full spectrum of brain and spine disease processes, including Alzheimer's disease and other dementias, multiple sclerosis, Parkinson's and Huntington's diseases, epilepsy, stroke and cerebrovascular disease, traumatic brain injury, brain and spinal tumors (with our Oncology Imaging division), spinal cord injury, and degenerative disorders of the spine.
The CNS Imaging division supports sophisticated imaging protocols incorporating structural and functional MRI, MRA, CT and CTA, CT and MR perfusion, diffusion and diffusion tensor imaging, PET and other nuclear imaging techniques, spectroscopy, catheter angiography, and transcranial Doppler ultrasound. Intrinsic Imaging works closely with sponsors from protocol development and imaging charter design through site qualification, image acquisition standardization, quality control, centralized independent review, quantitative analysis, and final data delivery.
Particular emphasis is placed on controlling imaging variability across sites, scanners, readers, and longitudinal timepoints—an essential consideration in CNS trials where subtle changes in anatomy, lesion burden, perfusion, diffusion, metabolism, or other imaging biomarkers may provide critical evidence of disease progression or therapeutic response. Through this combination of subspecialty physician expertise, advanced imaging capabilities, and disciplined central-review methodology, Intrinsic Imaging provides sponsors with the imaging infrastructure and scientific rigor required to support complex CNS clinical development programs.
In CNS trials, imaging biomarkers such as lesion burden, perfusion, diffusion, and metabolism often serve as primary or secondary imaging endpoints. We define each biomarker in the imaging charter and measure it consistently over time, so small changes reflect true disease progression or therapeutic response.
